[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591100":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":40,"locations":46,"responsibleParty":63,"collaborators":27,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":27,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":27,"overallStatus":48,"whyStopped":27,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Ocular Disease","EXPERIMENTAL","Patients: an imaging examination by each system (OTT + OCT + specular microscopy) will be carried out by two different operators, and several imaging images will be taken from different positions. These examinations will be performed at the inclusion visit and at follow-up visits as part of the usual management of the disease up to a maximum of 4 years",[13,14,15],"Device: Optical Transmission Tomography (OTT)","Device: Optical Coherence Tomography (OCT)","Device: Specular Microscopy (SM)",{"label":17,"type":18,"description":19,"interventionNames":20},"Healthy volunteers","ACTIVE_COMPARATOR","Healthy Volunteers: an imaging examination by each system (OTT + OCT + specular microscopy) will be carried out twice, at the inclusion visit and at 24 months (2 years), the maximum duration of participation for healthy volunteers. Several imaging sessions will be carried out by two different operators at different positions",[13,14,15],[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DEVICE","Optical Transmission Tomography (OTT)","Multiple imaging sessions added by research using the systems described (OTT) will be carried out by two different operators at different positions during these sessions.",[17,9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Optical Coherence Tomography (OCT)","Multiple imaging sessions (OCT) already used in standard of care will be performed by two different operators at different positions during these sessions.",[17,9],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Specular Microscopy (SM)","Multiple imaging sessions (SM) already used in standard of care will be performed by two different operators at different positions during these sessions.",[17,9],[37],{"name":38,"affiliation":5,"role":39},"Nacim BOUHERAOUA, PU-PH","PRINCIPAL_INVESTIGATOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":27,"email":45},"Nabil BROUK","CONTACT","00 33 1 40 02 11 44","nbrouk@15-20.fr",[47],{"facility":5,"status":48,"city":49,"state":27,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Paris","75012","France","FR",{"type":54,"coordinates":55},"Point",[56,57],2.3488,48.85341,{"lat":57,"lon":56},[60,61],{"name":42,"role":43,"phone":44,"phoneExt":27,"email":45},{"name":62,"role":39,"phone":27,"phoneExt":27,"email":27},"Nacim BOUHERAOUA",{"type":64,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100591100","ocular-examination-at-cell-resolution-with-optical-transmissiontomography-100591100",false,"NCT06976034","oCular Examination at Cell RESolution With Optical TransmissionTomography","CERES-OTT","Inclusion Criteria:\n\nFor Patients:\n\n* 200 subjects aged 18 to 80 years;\n* Male or female;\n* with an ocular disease affecting the cornea, ocular surface, lens (cataract) or glaucoma, or requiring refractive surgery or post-refractive surgery follow-up;\n* Are covered by the French Assurance Maladie;\n* Have signed an express, free and informed consent form.\n\nFor Healthy volunteers:\n\n* 100 subjects aged 18 to 80 years;\n* Male or female;\n* Healthy subjects with no known pathology directly or indirectly affecting ocular structures;\n* Covered by the French Assurance Maladie.\n* Having signed an express, free and informed consent form.\n\nExclusion Criteria:\n\nFor all participants:\n\n* Inability to hold a still position on a standard ophthalmic chin rest;\n* Conjunctivitis or other contagious contact disease in active phase;\n* Having an implanted pacemaker or other electronic medical device;\n* Having a predisposition to iridocorneal angle closure;\n* Vulnerable persons or persons under legal protection (pregnant or breast-feeding women; persons under guardianship,",true,"ALL","18 Years","80 Years",{"count":77,"type":78},300,"ESTIMATED","INTERVENTIONAL",[81],"NA","Understanding the pathogenesis of eye diseases has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems, such as optical coherence tomography (OCT), are limited in terms of resolution, acquisition speed or access to certain eye functions. Our team has participated in the development of a new generation of imaging technology known as optical transmission tomography (OTT), which enables imaging of the anterior parts of the eye with high cellular resolution, a wide field of view and reduced examination delay.",[84],"Glaucoma Associated With Other Ocular Disorders","2025-05-15",{"date":87,"type":88},"2025-05-16","ACTUAL",{"date":90,"type":88},"2024-11-12",{"date":92,"type":78},"2029-11-12",{"name":5,"class":6},1]